Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.

Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J.

Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.

2.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

3.

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.

Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P, Lai CJ.

Mol Cancer Ther. 2013 Jun;12(6):925-36. doi: 10.1158/1535-7163.MCT-12-1045. Epub 2013 Mar 27.

4.

Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M.

Clin Cancer Res. 2012 Aug 1;18(15):4104-13. doi: 10.1158/1078-0432.CCR-12-0055. Epub 2012 Jun 12.

5.

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C.

Cancer Res. 2010 May 1;70(9):3647-56. doi: 10.1158/0008-5472.CAN-09-3360. Epub 2010 Apr 13.

6.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538.

7.

BMP signaling induces cell-type-specific changes in gene expression programs of human keratinocytes and fibroblasts.

Fessing MY, Atoyan R, Shander B, Mardaryev AN, Botchkarev VV Jr, Poterlowicz K, Peng Y, Efimova T, Botchkarev VA.

J Invest Dermatol. 2010 Feb;130(2):398-404. doi: 10.1038/jid.2009.259. Epub 2009 Aug 27.

8.

Bone morphogenetic protein antagonist noggin promotes skin tumorigenesis via stimulation of the Wnt and Shh signaling pathways.

Sharov AA, Mardaryev AN, Sharova TY, Grachtchouk M, Atoyan R, Byers HR, Seykora JT, Overbeek P, Dlugosz A, Botchkarev VA.

Am J Pathol. 2009 Sep;175(3):1303-14. doi: 10.2353/ajpath.2009.090163. Epub 2009 Aug 21.

9.

CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.

Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C.

Clin Cancer Res. 2009 Jun 15;15(12):4046-57. doi: 10.1158/1078-0432.CCR-09-0152. Epub 2009 Jun 9.

10.

Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin.

Atoyan R, Shander D, Botchkareva NV.

J Invest Dermatol. 2009 Sep;129(9):2312-5. doi: 10.1038/jid.2009.58. Epub 2009 Mar 12. No abstract available.

11.

Oligonucleotide treatment increases eumelanogenesis, hair pigmentation and melanocortin-1 receptor expression in the hair follicle.

Atoyan RY, Sharov AA, Eller MS, Sargsyan A, Botchkarev VA, Gilchrest BA.

Exp Dermatol. 2007 Aug;16(8):671-7.

PMID:
17620094
12.

Involvement of the Edar signaling in the control of hair follicle involution (catagen).

Fessing MY, Sharova TY, Sharov AA, Atoyan R, Botchkarev VA.

Am J Pathol. 2006 Dec;169(6):2075-84.

13.

Bone morphogenetic protein signaling regulates the size of hair follicles and modulates the expression of cell cycle-associated genes.

Sharov AA, Sharova TY, Mardaryev AN, Tommasi di Vignano A, Atoyan R, Weiner L, Yang S, Brissette JL, Dotto GP, Botchkarev VA.

Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18166-71. Epub 2006 Nov 17.

14.

Changes in different melanocyte populations during hair follicle involution (catagen).

Sharov A, Tobin DJ, Sharova TY, Atoyan R, Botchkarev VA.

J Invest Dermatol. 2005 Dec;125(6):1259-67.

15.

Bone morphogenetic protein (BMP) signaling controls hair pigmentation by means of cross-talk with the melanocortin receptor-1 pathway.

Sharov AA, Fessing M, Atoyan R, Sharova TY, Haskell-Luevano C, Weiner L, Funa K, Brissette JL, Gilchrest BA, Botchkarev VA.

Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):93-8. Epub 2004 Dec 23.

16.

Noggin overexpression inhibits eyelid opening by altering epidermal apoptosis and differentiation.

Sharov AA, Weiner L, Sharova TY, Siebenhaar F, Atoyan R, Reginato AM, McNamara CA, Funa K, Gilchrest BA, Brissette JL, Botchkarev VA.

EMBO J. 2003 Jun 16;22(12):2992-3003.

Supplemental Content

Loading ...
Support Center